MS LifeLines® Reaches Milestone of Servicing One Million In-bound Calls
• Educational Support Service for Multiple Sclerosis Community Provides a Voice at the Other End


Rockland, Mass and New York – September 1, 2010 – EMD Serono, Inc. and Pfizer Inc announced today that MS LifeLines, an educational and support service which includes a call center, has achieved a milestone in servicing one million in-bound calls since its inception in 2002. MS LifeLines is sponsored by EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The service is available to the multiple sclerosis (MS) community, including people living with MS, their families and care partners.

“As an organization working to deliver innovative solutions, we are pleased to be able to provide our programs and services to the MS community and to continue to enhance all of our offerings,” said Fereydoun Firouz, President and CEO of EMD Serono, Inc. “We are proud of our long-standing heritage in serving the MS community, and reaching the one million call milestone is another demonstration of our long-term commitment in MS.”

“MS LifeLines is making a difference in the lives of people living with MS,” said Paul Richardson, Regional President, North America, Pfizer Specialty Care. “This service stands as another example of EMD Serono and Pfizer’s commitment to serving the patient communities and advancing treatments for serious diseases.”

MS LifeLines was first launched in 2002 as an educational resource for the MS community, sponsored by EMD Serono and Pfizer. One of its service offerings is a call center based in EMD Serono’s corporate headquarters in Rockland, Mass. The call center includes patient enrollment specialists, patient support specialists, nurse support specialists and reimbursement   specialists. People in the MS community can call any time, day or night and receive assistance. A live representative is available to answer calls 24 hours a day, seven days a week.

“Whether a person calls with a question about therapy or a question related to their insurance, the team at MS LifeLines is here to help lend a hand,” added Lauren Sweeney, patient support team member at MS LifeLines. “It is extremely rewarding to be able to make a difference. Receiving a diagnosis of MS can be overwhelming, and we’re here to help serve as a resource for the entire MS community.”

The programs and services provided by MS LifeLines continue to be enhanced to meet the needs of individuals impacted by MS and their loved ones. A patient access program, MS LifeLines Access Made Simple, was designed to assist eligible patients who need help in getting on therapy quickly. To learn more about the Access Made Simple program, visit In addition, other innovative service offerings have been introduced including MS LifeLines Rx. This web-based prescribing tool allows physicians to have access to another prescribing option instead of the paper process. For more information on the programs and services offered by MS LifeLines, visit

In the US, EMD Serono, Inc. and Pfizer Inc., co-promote Rebif (interferon beta-1a) for the treatment of patients with relapsing forms of multiple sclerosis.

About MS LifeLines® MS LifeLines is an educational support service committed to the MS community. Our mission is to offer support to people with MS, people on or considering Rebif® (interferon beta-1a) therapy, and the care partners who support them. The web site,, provides information on everything from personal stories to lifestyle tips. MS LifeLines also offers telephone support toll free at 1-877-447-3243.


About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that there are approximately 400,000 people in the United States living with MS. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.


About Rebif
Rebif is the only self-administered disease-modifying drug proven effective in reducing MRI lesion area and activity, reducing the frequency of relapses and slowing disability in relapsing MS.† Rebif is not approved for the treatment of chronic progressive MS.

† The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. Rebif is not approved for treatment of chronic progressive MS. Rebif is available in 22 mcg and 44 mcg prefilled, preassembled syringes and a titration pack by prescription only. Before beginning treatment, patients should discuss with their doctor the potential benefits and risks associated with Rebif. Let your doctor know if you have a history of depression, seizures, liver disease, thyroid problems, or blood cell count or bleeding problems, or if you have had previous allergic reactions to medications. Tell your doctor about all medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Rebif and other medicines may affect each other causing serious side effects. Talk to your doctor before you take any new medicines. Rebif is not recommended for women who are or plan to become pregnant. Potential serious side effects of Rebif include depression and risk of suicide, liver problems, risk to pregnancy, injection-site problems, and severe allergic reactions. Allergic reactions are rare and may be associated with difficulty in breathing and loss of consciousness, which require immediate medical attention. The most common side effects with Rebif are injection-site reactions, flu-like symptoms (fever, chills, muscle aches, tiredness), depression, abdominal pain, increased liver enzymes, and blood cell count decreases. Let your doctor know if you have any of these symptoms or feel sad, tired, hot or cold, or experience hives, rashes, bruising, yellowing of the skin, or a change in body weight (gain or loss). This information is not intended to replace discussions with your doctor. For additional information about Rebif, please consult the Prescribing Information and Medication Guide at and talk to your doctor. You can also visit or call toll-free 1-877-44-REBIF (1-877-447-3243). Rebif is available by prescription only.


About EMD Serono, Inc. 
EMD Serono is the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has 1,300 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.


About Merck KGaA, Darmstadt, Germany 
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of €15.0 billion in 66 countries.

Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Media Contacts:

Melissa Hill Director, Communications

EMD Serono, Inc.



Gwendolyn E. Fisher

Media Relations, Specialty Care Worldwide Communications

Pfizer Inc.

T. 484.865-5160 C. 215-407-1548



You have accessed, but for users from your part of the world, we originally designed the following web presence

Let's go

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement